/
Oncology
Acute Lymphoblastic Leukemia
186
Pipeline Programs↗
245
Active Trials↗
99
Companies Involved↗
Acute Lymphoblastic Leukemia is a highly competitive landscape with 186 programs across 99 companies. The most active players are Gilead, Newave Pharmaceutical Inc, Chongqing Precision Biotech Co., Ltd. 48 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical48
Phase 144
Phase 246
Phase 348
Approved
No programs
Analysis
Modality Breakdown
62%
Small molecule
98 of 159 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 159 classified programs, each share of the total. Modality classified for 95% of 186 pipeline programs.
Analysis
Trial Status
825
clinical trials
Completed359 · 44%
Recruiting147 · 18%
Terminated96 · 12%
Unknown status84 · 10%
Active, not recruiting72 · 9%
Withdrawn32 · 4%
Other35 · 4%
Clinical Trials
Trial Activity
825 trials
Page 1 of 55
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)